Abologix

Abologix is a biopharmaceutical spin-out from the University of Geneva and Geneva University Hospitals, founded in 2018 in Geneva, Switzerland. The company specializes in the development of monoclonal antibodies designed to selectively block novel oncological targets, specifically the Junction Adhesion Molecule C (JAM-C) and the Olfactomedin-like protein 3 (Olfml3). Their lead preclinical candidate, H225, targets JAM-C to address B-cell lymphomas that have become resistant to standard treatments, with potential applications for various solid tumors.

This work is critical for patients who have exhausted first-line therapies and face poor prognoses, such as those with Mantle Cell Lymphoma. By focusing on these specific protein targets, Abologix aims to introduce a new generation of targeted cancer inhibitors. The company has secured support through the Innosuisse innovation program and funding from the KICK FUND to advance its preclinical development and research programs. Their approach is rooted in long-standing academic research into cell adhesion molecules and tumor-associated angiogenesis, aiming to eventually transition these therapies into clinical trials.